Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation.
B E Clurman , R J Sheaff , K Thress , M Groudine
Genes & Development 10 ( 16) 1979 -1990
430
1996
OA 09.02 Osimertinib Resistance Mediated by Loss of EGFR T790M Is Associated with Early Resistance and Competing Resistance Mechanisms
G Oxnard , Y Hu , K Mileham , P Tracy
Journal of Thoracic Oncology 12 ( 11) S1767 -S1768
9
2017
Genomic analysis of tumor and plasma in T790M mutant positive EGFR lung cancer patients before and after osimertinib treatment
JC Yang , C Yu , J Shih , C Ho
JOURNAL OF THORACIC ONCOLOGY 12 ( 11) S2230 -S2231
1
2017
A Clinically-Validated Universal Companion Diagnostic Platform for Cancer Patient Care
J Sun , Y Li , C Milbury , J Skoletsky
JOURNAL OF THORACIC ONCOLOGY 12 ( 11) S2117 -S2118
2017
Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the TRK kinase pathway
K Thress , T MacIntyre , H Wang , ZY Liu
EJC SUPPLEMENTS 6 ( 12) 180 -180
2008
135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC
GR Oxnard , KS Thress , RS Alden , R Lawrance
Journal of Thoracic Oncology 11 ( 4)
8
2016
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
GR Oxnard , JC-H Yang , H Yu , S-W Kim
Annals of Oncology 31 ( 4) 507 -516
253
2020
The Presence of Circulating Tumor DNA in Ovarian Cancer Patients After Platinum-Based Chemotherapy
C Eakin , K Sun , M Shan , Y Zhou
Gynecologic Oncology 156 ( 3)
2020
Design, execution, and preliminary biomarker results from paired tumor biopsy cohorts of the AZD9291 AURA trial
Joseph Geradts , Fiona Blackhall , Karthick Vishwanathan , Kenneth Thress
Journal of Thoracic Oncology
1
2015
Abstract PR05: ERK pathway activation is associated with acquired resistance to AZD9291, a third-generation irreversible inhibitor targeting EGFR sensitizing (EGFRm+) and resistance (T790M) mutations in NSCLC
Cath Eberlein , Katie Al-Kadhimi , Sarah Ross , Henry Brown
Clinical Cancer Research 21
2015
Mitochondria at the crossroad of apoptotic cell death.
Kenneth Thress , Sally Kornbluth , Jesse J. Smith
Journal of Bioenergetics and Biomembranes 31 ( 4) 321 -326
50
1999
Abstract LB-249: Examination of analytical factors impacting concordance of plasma-tumor testing by next-generation sequencing (NGS)
Brian Dougherty , Ambar Ahmed , Tristan Lubinski , Aleksandra Markovets
Cancer Research 77
2
2017
A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Ian Flinn , Nancy L. Bartlett , Kristie A. Blum , Kirit M Ardeshna
Blood 124 ( 21) 1725 -1725
3
2014
Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
Kenneth Thress , Terry MacIntyre , Haiyun Wang , Dave Whitston
Molecular Cancer Therapeutics 8 ( 7) 1818 -1827
59
2009
Scythe: a novel reaper‐binding apoptotic regulator
Kenneth Thress , William Henzel , Wendy Shillinglaw , Sally Kornbluth
The EMBO Journal 17 ( 21) 6135 -6143
116
1998
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of technologies to support the clinical development of AZD9291.
Kenneth Thress , Roz Brant , Hedley Carr , Helen Brown
Journal of Clinical Oncology 32 ( 15_suppl) 8092 -8092
5
2014
AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts
Radhika Iyer , Carly R. Varela , Jane E. Minturn , Ruth Ho
Cancer Chemotherapy and Pharmacology 70 ( 3) 477 -486
33
2012
A family of ubiquitin-like proteins binds the atpase domain of hsp70-like stch
Frederic J. Kaye , Sanjay Modi , Irena Ivanovska , Eugene V. Koonin
FEBS Letters 467 ( 2) 348 -355
93
2000
Abstract LB-146: A phase II randomized placebo-controlled study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, plus paclitaxel (P) vs P alone in patients (pts) with low HER2-expressing advanced breast cancer (BC) (THYME).
José Baselga , Roberto Hegg , Maria Vidal Losada , Tatiana Vidaurre
Cancer Research 73
4
2013
Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
Chia-Chi Hsu , Bin-Chi Liao , Wei-Yu Liao , Aleksandra Markovets
Journal of Thoracic Oncology 15 ( 1) 50 -61
46
2020